XtalPi Holdings (FRA:V0I) ROE %: 1.00% (As of Dec. 2025) — 47% Below Median


FRA:V0I XtalPi Holdings Ltd FRA:V0I
20 GF Score
Price €0.73
! 7 Warning Signs
View Full Analysis

What is XtalPi Holdings ROE %?

XtalPi Holdings FRA:V0I -0.68% 20 ROE % is 1.00% as of Dec. 2025, which is 47% below its 10-year median of 1.87. GuruFocus rates FRA:V0I with a GF Score™ of 20/100. The stock has 7 warning signs investors should review. Among 625 Healthcare Providers & Services companies, XtalPi Holdings ranks worse than 63.04% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. XtalPi Holdings's annualized net income for the quarter that ended in Dec. 2025 was €9.93 Mil. XtalPi Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €991.19 Mil. Therefore, XtalPi Holdings's annualized ROE % for the quarter that ended in Dec. 2025 was 1.00%.

The historical rank and industry rank for XtalPi Holdings's ROE % or its related term are showing as below:

FRA:V0I' s ROE % Range Over the Past 10 Years
Min: 1.83   Med: 1.87   Max: 1.87
Current: 1.83

During the past 5 years, XtalPi Holdings's highest ROE % was 1.87%. The lowest was 1.83%. And the median was 1.87%.

FRA:V0I's ROE % is ranked worse than
63.04% of 625 companies
in the Healthcare Providers & Services industry
Industry Median: 5.84 vs FRA:V0I: 1.83

XtalPi Holdings  (FRA:V0I) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=9.93/991.185
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(9.93 / 69.246)*(69.246 / 1085.4075)*(1085.4075 / 991.185)
=Net Margin %*Asset Turnover*Equity Multiplier
=14.34 %*0.0638*1.0951
=ROA %*Equity Multiplier
=0.91 %*1.0951
=1.00 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=9.93/991.185
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (9.93 / 14.49) * (14.49 / -110.03) * (-110.03 / 69.246) * (69.246 / 1085.4075) * (1085.4075 / 991.185)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.6853 * -0.1317 * -158.9 % * 0.0638 * 1.0951
=1.00 %

Note: The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


XtalPi Holdings ROE % Related Terms


XtalPi Holdings ROE % Historical Data

* Premium members only.

The historical data trend for XtalPi Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XtalPi Holdings ROE % Chart

XtalPi Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
0.00 0.00 0.00 0.00 1.81

XtalPi Holdings Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Get a 7-Day Free Trial 0.00 0.00 -14.01 2.93 1.00

FRA:V0I vs VEEV, BTSG, TEM: ROE % Comparison

For the Health Information Services subindustry, XtalPi Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XtalPi Holdings ROE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, XtalPi Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where XtalPi Holdings's ROE % falls into.


FRA:V0I
20GF Score
XtalPi Holdings Ltd FRA:V0I
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XtalPi Holdings ROE % Calculation

XtalPi Holdings's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=15.005/( (519.92+1137.788)/ 2 )
=15.005/828.854
=1.81 %

XtalPi Holdings's annualized ROE % for the quarter that ended in Dec. 2025 is calculated as

ROE %=Net Income (Q: Dec. 2025 )/( (Total Stockholders Equity (Q: Jun. 2025 )+Total Stockholders Equity (Q: Dec. 2025 ))/ count )
=9.93/( (844.582+1137.788)/ 2 )
=9.93/991.185
=1.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2025) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 1.00% mean?
XtalPi Holdings (FRA:V0I) has a ROE % of 1.00% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on XtalPi Holdings and its competitors. This is 47% below median its historical median of 1.87. Over the past decade, XtalPi Holdings' ROE % has ranged from 1.83 to 1.87. According to the industry distribution chart, XtalPi Holdings ranks #394 out of 625 companies in the Healthcare Providers & Services industry, placing it in the top 63%.
Is XtalPi Holdings' ROE % too high?
XtalPi Holdings' current ROE % of 1.00% is 47% below median its 10-year median of 1.87. Over the past 10 years, this metric has ranged from a low of 1.83 to a high of 1.87. The Healthcare Providers & Services industry median ROE % is 5.84. XtalPi Holdings' value of 1.00% is 82.9% below this industry median. Based on the distribution chart, XtalPi Holdings ranks #394 out of 625 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, XtalPi Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does XtalPi Holdings' ROE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, XtalPi Holdings ranks #394 out of 625 companies for ROE %. This places XtalPi Holdings in the lower half of its industry. The industry median ROE % is 5.84. XtalPi Holdings' value of 1.00% is 82.9% below this benchmark. Historically, XtalPi Holdings' own ROE % has ranged from 1.83 to 1.87 over the past decade. While the company's 10-year median is 1.87 vs. the industry median of 5.84, XtalPi Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.84, based on 625 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XtalPi Holdings's current ROE % of 1.00% is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on XtalPi Holdings and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XtalPi Holdings's current ROE % is 1.00%, which is 47% below median its own 10-year median of 1.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XtalPi Holdings stock overvalued right now?
XtalPi Holdings (FRA:V0I) has a current ROE % of 1.00%. The current ROE % is 1.00%, which is 47% below median its 10-year median of 1.87 and 82.9% below the Healthcare Providers & Services industry median of 5.84. XtalPi Holdings' overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For XtalPi Holdings (FRA:V0I), the current ROE % is 1.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XtalPi Holdings Business Description

Other Exchanges 02228:Hong Kong
Address No. 2 Hongliu Road, 3rd floor, Second Phase of the International, Biomedical Industrial Park, Futian District, Shenzhen, CHN
XtalPi Holdings Ltd is a research platform company powered by artificial intelligence (AI) and robotics. It is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. The company combines quantum physics, AI, cloud computing, and large-scale robotics to provide research & development solutions, services, and products for pharmaceuticals, biotechnology, renewable energy, and materials industries globally. The company has a single segment that is intelligent robotics solutions and drug discovery solutions (including one-stop drug discovery solutions). The firm generates the majority of its revenue from Drug discovery solutions, and a smaller portion of revenue is derived from AI for Science intelligent solutions.
20GF Score

Get the complete analysis for FRA:V0I

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.73
Price